Close Menu

The New York Times' Nicholas Wade likens NIH's funding of basic research to the management of a stock index fund — "they buy everything in the market, and the few spectacular winners make up for all the disasters." In fact, basic research is so risky, he adds, that only the government is interested in paying for it. "It is a venture that produces far fewer hits than misses," Wade says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.